Figure 2.

Number and percentage of major and minor discrepancies for each ARV– 3-level interpretation, excluding efavirenz, nevirapine and emtricitabine.

Jiamsakul et al. BMC Research Notes 2012 5:582   doi:10.1186/1756-0500-5-582
Download authors' original image